Please login to the form below

Not currently logged in
Email:
Password:

Idalopirdine

This page shows the latest Idalopirdine news and features for those working in and with pharma, biotech and healthcare.

Lundbeck signs $1.1bn deal for Prexton and Parkinson’s drug

Lundbeck signs $1.1bn deal for Prexton and Parkinson’s drug

the failure of Alzheimer’s candidate idalopirdine.

Latest news

  • Axovant joins ever-growing Alzheimer’s failure club Axovant joins ever-growing Alzheimer’s failure club

    5-HT6 inhibitor Intepirdine followsin the footsteps of Lundbeck's idalopirdine. Axovant’s phase III trial of Alzheimer’s disease (AD) candidate intepirdine has ended in failure, an outcome that ... s idalopirdine, which suffered a similar late-stage

  • Lundbeck trial failure dashes hopes in Alzheimer's once again Lundbeck trial failure dashes hopes in Alzheimer's once again

    Idalopirdine (Lu AE58054) appeared to be safe and showed evidence of "weak efficacy" in the phase III STARSHINE study, which enrolled patients with mild to moderate Alzheimer's. ... Idalopirdine is being developed in partnership with Japanese drugmaker

  • Surging sales of Lundbeck's CNS drugs assist recovery Surging sales of Lundbeck's CNS drugs assist recovery

    new Otsuka-partnered drug - idalopirdine - in trials for Alzheimer's disease. ... Idalopirdine (Lu AE58054) is being tested as an add-on therapy to boost the effects of cholinesterase inhibitors in Alzheimer's, so could be a less risky proposition than

  • Axovant takes Alzheimer's drug into phase III Axovant takes Alzheimer's drug into phase III

    Lundbeck and Otsuka also have a 5-HT6 antagonist called idalopirdine (Lu AE58054) in phase III trials that are due to report data between November and mid-2016.

More from news
Approximately 2 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
bmore group

OUR PROMISE: BETTER HEALTH FROM TRIAL TO TREATMENT.We are a full service, independent network of specialist agencies under one roof....

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics